| 영문 | endocrine gland | 한글 | 내분비샘 |
|---|---|---|---|
| 설명 | 신체의 내부로 분비가 되어서 다른 세포의 기능이나 활성의 변화를 일으키는 물질인 호르몬을 분비하는 곳을 이르는 말이다. 대표적인 내분비샘은 갑상샘, 부갑상샘, 부신, 이자, 뇌하수체, 난소, 고환, 솔방울샘, 가슴샘 등이다. 마지막에 나오는 2개의 기관은 내분비 기능을 하는 것으로 생각이 되지만 확실히 그것이 무슨 기능을 하는 지에 대해선 아직까지 정확하게 밝혀지지 않고 있다.  |
||
| 영문 | multiple sclerosis | 한글 | 다발경화증 |
|---|---|---|---|
| 설명 | 신경축삭을 둘러싸고 있는 말이집(myelin sheath)의 파괴로 인한 병적상태를 말함. 파괴된 말이집은 흉터를 남기게 되어 신경축삭을 통한 신경전달이 제대로 되지 않아 운동, 감각, 자율신경 모두의 신경전달장애가 나타난다. 이 병터는 어디서나 나타날 수 있어서 그 장애가 나타나는 부위에 따라 서로 다른 증상을 호소한다. |
||
| 영문 | multiple myeloma | 한글 | 다발골수종 |
|---|---|---|---|
| 설명 | 다발성 원발성골종양. 머리뼈-갈비뼈-복장뼈-척추뼈-골반 등에 잘 나타나고, 물렁물렁한 종괴를 형성하며, 뼈의 흡수가 일어나고, 40~60세 남자에게 많이 발생한다. 골수종 종양세포는 형질세포에서 유래한 것이어서 형질세포종이라고도 한다. 과거에는 형질세포성골수종 이외에는 다른 골수조혈요소에서 생기는 골수종이라고 생각했지만 현재는 부정되고 있다. 형질세포는 원래 면역글로불린을 생산하는 세포이며, 그것이 종양화한 다발 골수종 환자에서도 대부분 혈청 속에 면역 글로불린이 증가된 것을 볼 수 있다. 증가한 글로불린은 IgG나 IgA인 경우가 많지만 다른 형도 있다. 골수종 환자 약 50%는 오줌에서 벤스죤스단백질이 검출되는데, 이 단백질의 축적에 의해 요세관이 파괴되고, 콩팥경화가 일어난다. 골수종 환자에서는 혈청단백 이상으로 가끔 아밀로이드증이 나타난다. 뼈 X선 소견으로서는 도려낸 병터, 골융해상, 병적골절이 관찰된다. |
||
| 영문 | multiple personality | 한글 | 다인성 인격 |
|---|---|---|---|
| 설명 | 해리성 정신장애의 하나로 나타난다. 한 사람이 여러 사람의 성격을 소유하고 있는 것으로 마치 “지킬박사와 하이드 씨”와 같은 경우이다. 아마, 현재 자신의 처지에서 벗어나고 싶은 무의식적인 욕망에서 비롯되는 것으로 여겨진다. |
||
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
|---|---|
| FMEN | familial multiple endocrine neoplasia |
| MEN | multiple endocrine neoplasia |
| MEN-I | multiple endocrine neoplasia, type I |
| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
| MEN | Multiple Endocrine Neoplasia |
|---|---|
| MEN I | Multiple Endocrine Neoplasia |
| MEN 1 | Multiple Endocrine Neoplasia Type 1 |
| MEN2a | Multiple Endocrine Neoplasia Type 2a |
| MEN-I | Multiple Endocrine Neoplasia Type I |
| multiple endocrine neoplasia 2 | <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia Synonym: Sipple syndrome (12 Dec 1998) |
|---|
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |
|---|---|
| multiple endocrine neoplasia 1 | <radiology> Multiple endrocrine neoplasia syndrome three P's. Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%). Synonym: Wermer syndrome (12 Dec 1998) |
| multiple endocrine neoplasia 3 | <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B Synonym: Schimke, marfanoid syndrome (12 Dec 1998) |
| multiple endocrine neoplasia type 1 | A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients. (12 Dec 1998) |
| multiple endocrine neoplasia type 2 | <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. (27 Sep 1997) |
| multiple endocrine neoplasia type 2a | A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands. (12 Dec 1998) |
| multiple endocrine neoplasia type 2b | A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas. (12 Dec 1998) |
| multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
| multiple endocrine deficiency syndrome | <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis. Synonym: multiple glandular deficiency syndrome. (05 Mar 2000) |
| familial multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
| cervical intraepithelial neoplasia | A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation. Origin: Gr. Plassein = to form (27 Sep 1997) |
| prostatic intraepithelial neoplasia | A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer. (12 Dec 1998) |
| neoplasia | <oncology, pathology> Literally new growth, usually refers to abnormal new growth and thus means the same as tumour, which may be benign or malignant. Unlike hyperplasia, neoplastic proliferation persists even in the absence of the original stimulus. Origin: Gr. Plassein = to form (18 Nov 1997) |
| lobular neoplasia | <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma. Synonym: lobular carcinoma in situ, lobular neoplasia. (05 Mar 2000) |
| bone diseases, endocrine | Diseases of the bones related to hyperfunction or hypofunction of the endocrine glands. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|